Developments in the pharmacological treatment of schizophrenia.
Schizophrenia is, at once, a biological disease, a neuropsychological disorder and a dysfunction of social interactions. This presents clinicians with a series of problems with regards to therapy. In the first section of this article, some of the clinical challenges that face those attempting to develop new drugs, are summarised. Several potential pharmacological therapeutic targets that have been, and are continuing to be used, in the development of new antipsychotic drugs, are then considered. This is followed by an outline of the pharmacological and clinical profiles of some of the newer generation antipsychotics, as well as investigational drugs in the pipeline for schizophrenia. Finally, the implications of the introduction of these new drugs for the management of schizophrenia, are discussed.
Kuperberg
Gina
G
Department of Psychological Medicine, Institute of Psychiatry, London, UK. kuperber@mail.nmr.mgh.harvard.edu
Kerwin
Robert
R
Murray
Robin
R
D000818:Animals; D014150:Antipsychotic Agents / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism; D013678:Technology, Pharmaceutical / Q000639:trends*
D014150:Antipsychotic Agents